Somatostatin receptor 2 targeting in small cell lung carcinoma: perspectives
Metrics: PDF 675 views | Full Text 991 views | ?
Jonathan M. Lehman1,2,3 and Pierre P. aMassion1,2,3
1 Division of Medical Oncology, Thoracic Program, Vanderbilt Ingram Cancer Center, Nashville, TN, USA
2 Thoracic Program, Vanderbilt Ingram Cancer Center, Nashville, TN, USA
3 Veterans Affairs, Tennessee Valley Healthcare System, Nashville Campus, Nashville, TN, USA
|Jonathan M. Lehman,||email:||firstname.lastname@example.org|
Keywords: small cell lung cancer; somatostatin receptor 2; antibody-drug conjugate; peptide drug conjugate; perspectives
Received: June 18, 2019 Accepted: June 29, 2019 Published: July 30, 2019
Small Cell lung carcinoma (SCLC) is the most lethal and aggressive subtype of lung cancer. Novel targeting approaches and agents are desperately needed. In this perspectives, we briefly explore recent data published in the International Journal of Cancer suggesting Somatostatin Receptor 2 (SSTR2) as a viable target for SCLC, summarize the current clinical trial space, and describe promising new research and clinical directions for Somatostatin Receptor 2 targeting in SCLC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.